Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma

TAKAYOSHI ROKKAKU1,2, RYUICHIRO KIMURA1,3, CHIE ISHIKAWA1,3, TAKESHI YASUMOTO4, MASACHIKA SENBA5, FUMINORI KANAYA5 and NAOKI MORI1

Departments of 1Microbiology and Oncology and 2Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215; 3Transdisciplinary Research Organization for Subtropics and Island Studies, University of the Ryukyus, Nishihara, Okinawa 903-0213; 4Marine Bio Industry Division, Okinawa Science and Technology Promotion Center, Naha, Okinawa 900-0029; 5Department of Pathology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan

Received April 25, 2013; Accepted June 7, 2013

DOI: 10.3892/ijo.2013.1920

Abstract. Survival of osteosarcoma patients hinges on prevention or treatment of recurrent and metastatic lesions. Therefore, novel chemotherapeutics for more effective treatment and prevention of this disease are required. Carotenoids are natural pigments and exhibit various biological functions. We evaluated the anti-osteosarcoma properties of several carotenoids. Among carotenoids, fucoxanthin and its metabolite fucoxanthinol, inhibited the cell viability of osteosarcoma cell lines. Fucoxanthinol induced G1 cell cycle arrest by reducing the expression of cyclin-dependent kinase 4, cyclin-dependent kinase 6 and cyclin E and apoptosis by reducing the expression of survivin, XIAP, Bcl-2 and Bcl-xL. Apoptosis was associated with activation of caspases-3, -8 and -9. In addition, fucoxanthinol inhibited the phosphorylation of phosphoinositide-dependent kinase 1 and Akt and the downstream glycogen synthase kinase 3β, resulting in downregulation of β-catenin. Fucoxanthinol inhibited the cell migration and invasion of osteosarcoma cells. It also reduced matrix metalloproteinase-1 expression and the activator protein-1 signal. Treatment of mice inoculated with osteosarcoma cells with fucoxanthin inhibited the development of osteosarcoma in mice. Fucoxanthin and fucoxanthinol inhibit cell growth, migration and invasion and induce apoptosis of osteosarcoma cells at least in part by inhibiting Akt and activator protein-1 pathways. Our findings provide a rationale for clinical evaluation of these novel agents in osteosarcoma.

Introduction

Osteosarcoma is the most frequent malignant bone tumor in children and adolescents and the estimated worldwide incidence ranges between 3 and 4.5 per million (1). Long-term survival in localized osteosarcoma has increased substantially from 10-20% when surgery as single treatment was used before the 1980’s up to 20-60% from 1985 onwards. The improvement in survival has been attributed to the use of intensive multi-agent chemotherapy in combination with advanced surgery. However, since then no substantial further improvement of survival has been reported (2). Despite aggressive multimodal therapy, this devastating tumor often acquires drug resistance and metastasizes (3). The most frequent site for metastatic presentation is the lung (3). Death from osteosarcoma is usually the result of progressive pulmonary metastasis with respiratory failure due to widespread disease (3). Hence, there is a real need to develop novel approaches for the treatment and prevention of osteosarcoma and efficient inhibition of metastasis, especially to the lung.

The role of carotenoids in reducing the risk of cancer has been postulated for several decades (4). Fucoxanthin, one of the most abundant carotenoids found in edible brown algae, has received much attention over the last few years as cancer chemopreventive and chemotherapeutic agent (5). Dietary fucoxanthin is deacetylated into fucoxanthinol in the intestinal tract by lipase and esterase from the pancreas or in intestinal cells and incorporated as fucoxanthinol from the digestive tract into the blood circulation system in mammals (5). These carotenoids exhibit antitumor effects in several malignant cell lines without affecting normal cells (5,6). The main mechanism is suggested to be the regulatory effects of fucoxanthin and fucoxanthinol on molecules related to apoptosis and cell cycle (5,6). Furthermore, it has been shown that fucoxanthin has chemopreventive activities in a variety of models of cancer (5). However, to date, there is no information on fucoxanthin- and fucoxanthinol-induced inhibition of cell growth, migration and invasion of human bone cancer cells. In this study, we investigated the effects of fucoxanthin and...
fucoxanthinol on cell cycle, apoptosis, migration and invasion of osteosarcoma cells. Furthermore, we also investigated the possible molecular targets of anti-osteosarcoma activities of fucoxanthin and fucoxanthinol.

Materials and methods

Cell lines. The human osteosarcoma cell lines, Saos-2, MNNG/HOS (MNNG) and 143B and mouse osteosarcoma cell line, LM8, were cultured in Roswell Park Memorial Institute-1640 or Eagle's minimum essential medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 U/ml penicillin and 50 µg/ml streptomycin at 37˚C in a humidified atmosphere with 5% CO₂. Both 143B cell line with high metastatic potential and MNNG cell line with low metastatic potential, are derived from TE85 human osteosarcoma cell line (7,8).

Reagents. β-carotene and astaxanthan were purchased from Wako Pure Chemical Industries (Osaka, Japan). Fucoxanthin was extracted from brown seaweed Cladophora okamuranus Tokida using acetone as solvent and purified by column chromatography, liquid-liquid partition and re-crystallization up to >95% purity. Further purification was performed by RP-HPLC up to >98% purity, for in vitro assay. Fucoxanthinol was prepared by enzymatic hydrolysis of purified fucoxanthin using porcine pancreatic lipase. For this purpose, 195 mg of fucoxanthin, 2 g of sodium taurocholate and 2 g of porcine pancreatic lipase (Type II; Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 30 ml of 0.1 M sodium phosphate buffer (pH 7.0). The reaction buffer was incubated at 37˚C for 3 h. Fucoxanthinol was purified by ODS column chromatography, liquid-liquid partition and re-crystallization. In the experiment, we prepared 142 mg of purified fucoxanthinol (>95% purity, 72% yield). Further purification was achieved by RP-HPLC up to >98% purity, for in vitro assay. The identity and purity of the products were confirmed by comparison with reference fucoxanthin (Wako Pure Chemical Industries) and data available in the literature. Tumor necrosis factor-α (TNF-α) and the caspase inhibitor, Z-VAD-fmk, were purchased from PeproTech (Rocky Hill, NJ, USA) and Promega (Madison, WI, USA), respectively. Antibodies to Bcl-2, cyclin E, cyclin-dependent kinase (CDK)2, CDK4, CDK6 and actin were purchased from NeoMarkers (Fremont, CA, USA). Antibodies to XIAP and cyclin D1 were obtained from Medical and Biological Laboratories (Nagoya, Japan). Antibodies to IkBa, phospho-IkBa (Ser32 and Ser36), Akt, phospho-Akt (Thr308), phospho-Akt (Ser473), phosphoinositide-dependent kinase 1 (PDK1), phospho-PDK1 (Ser241), phospho-glycogen synthase kinase 3β (GSK3β) (Ser9), caspase-8, cleaved caspase-3, cleaved caspase-9, cleaved poly(ADP-ribose) polymerase (PARP), phospho-caspase-9 (Thr125), survivin, Bak and Bcl-2 were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies to GSK3β and β-catenin were obtained from BD Transduction Laboratories (San Jose, CA, USA). Antibodies to cyclin D2, phospho-p130 (Ser952) and activator protein-1 (AP-1) subunits c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB and JunD for super-shift assay were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody to matrix metalloproteinase-1 (MMP-1) was purchased from Daiichi Fine Chemical (Takaoka, Japan).

Cell culture, viability and apoptosis assays. For the viability assay, the cell lines were plated in 96-well culture plates for 24 h in complete culture medium. Different concentrations of each carotenoid were added and the cells were incubated for 24 h. Cell viability was evaluated by measuring the mitochondrial-dependent conversion of the water-soluble tetrazolium (WST)-8 (Nacalai Tesque, Kyoto, Japan) to a colored formazan product. WST-8 (5 µl) was added for the last 4 h of incubation and absorbance at 450 nM was measured using an automated microplate reader. Apoptotic events in cells were detected by staining with phycoerythrin-conjugated Apo2.7 antibody (Beckman Coulter, Marseille, France) (9) and analyzed by flow cytometry (Epics XL, Beckman Coulter, Fullerton, CA, USA). Since the viability of 20 µM fucoxanthin-treated Saos-2 cells at 24 h was 0%, electrophoretic mobility shift and protein expression assays were carried out at 9-12 h for incubation.

Assessment of caspase activities. After treatment with indicated concentrations of fucoxanthinol (5, 10 and 20 µM) for 9 h, the activities of caspases-3/7, -8 and -9 were evaluated, respectively, using Caspase-Glo 3/7, 8 and 9 assay kits (Promega) according to the manufacturer's protocol. The luminescence that is proportional to caspases-3/7, -8 and -9 activities was determined by a luminometer.

Cell cycle analysis. Cells were treated with fucoxanthinol at a concentration of 20 µM. After 9 h of incubation, cell cycle analysis was performed with the CycleTest Plus DNA reagent kit (Becton-Dickinson Immunocytometry Systems, San Jose, CA, USA). Briefly, cells were washed with a buffer solution containing sodium citrate, sucrose and DMSO, suspended in a solution containing RNase A and then stained with 125 µg/ml propidium iodide for 10 min. Cell suspensions were analyzed on a Coulter EPICS XL using EXPO32 software. The population of cells in each cell cycle was determined with the MultiCycle software.

Reverse transcription-PCR (RT-PCR). Total cellular RNA from cells was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA) according to the protocol provided by the manufacturer. First-strand cDNA was synthesized from 1 µg total cellular RNA using a PrimeScript RT-PCR kit (Takara Bio Inc., Otsu, Japan) with random primers. The primers used were 5'-GGTGCCCAGTGGTTGAAAAAT-3' (forward) and 5'-CATCACTTCTTTCCCCGAATC-3' (reverse) for MMP-1 and 5'-GCCAAGGTCATCCATGACAACTTTGG-3' (forward) and 5'-GCCGTCGTTTCACCACCTTCTTGTGC-3' (reverse) for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The length of RT-PCR was 40 cycles for MMP-1 and 27 cycles for GAPDH. The PCR products were fractionated on 2% agarose gels and visualized by ethidium bromide staining.

Western blot analysis. Cells were lysed in a buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate, 10% glycerol, 6% 2-mercaptoethanol and 0.01% bromphenol blue. Equal amounts of protein (20 µg) were subjected to electrophoresis on sodium dodecyl sulfate-polyacrylamide gels, followed by transfer to a polyvinylidene difluoride membrane and sequential probing with the specific antibodies. The bands
were visualized with an enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ, USA).

**Preparation of nuclear extracts and electrophoretic mobility shift assay (EMSA).** Nuclear extracts were obtained as described by Antalis and Godbolt (10) with modifications and EMSA was performed as described previously (11). Briefly, 5 µg of nuclear extract was incubated with 32P-labeled probes. The DNA-protein complex was separated from the free oligonucleotides on 4% polyacrylamide gel. To examine the specificity of the probe, we preincubated unlabeled competitor oligonucleotides with nuclear extracts for 15 min before incubation with probes. The probes or competitors used were prepared by annealing the sense and antisense synthetic oligonucleotides as follows: for the wild-type AP-1 element of the MMP-1 gene, 5'-GATCTTATAAAGCATGATCCAGACACCTCT-3'; for the AP-1 element mutant of the MMP-1 gene, 5'-GATCTTAAAAGCATGAGGAGCACCTCT-3' (sites of mutation are indicated in lowercase); for the AP-1 element of the interleukin (IL)-8 gene, 5'-GATCGTGATGACTCGAGTT-3'; and for the nuclear factor-κB (NF-κB) element of the IL-2 receptor α chain (IL-2Rα) gene, 5'-GATCCCCGAGGGGATCTCCCTCCTC-3'. The oligonucleotide 5'-GATCTGTCCGATGCAAAATCAGAAG-3', containing the consensus sequence of the octamer binding motif, was used to identify specific binding of the transcription factor, Oct-1. The underlined sequences above are the AP-1, NF-κB and Oct-1 binding sites, respectively. To identify transcription factors in the DNA-protein complex detected by EMSA, we used antibodies specific for various AP-1 family proteins, including c-Fos, fosB, Fra-1, Fra-2, c-Jun, JunB and JunD (Santa Cruz Biotechnology), to elicit a supershift DNA-protein complex formation. These antibodies were incubated with the nuclear extracts for 45 min at room temperature before incubation with radiolabeled probe.

**Cell invasion assay.** ACEA electrosensing x16 microtiter plates were coated with 215 µg/ml rat tail type I collagen (BD Biosciences, San Jose, CA, USA). Saos-2 cells were seeded at 3x10⁵ cells/ml in 100 µl of serum-free medium without or with fucoxanthinol (50 or 100 nM) in the upper chamber with 8-µm pore size and the lower chamber contained 10% serum. The ACEA plate was connected to the ACEA Device Station at 37°C and the cells that invaded through type I collagen were monitored every 1 h in real-time by the ACEA Sensor Analyzer for 24 h and quantitated using ACEA RT-CES Integrated software.

**Cell migration assay.** Saos-2 cell migration was also assessed using ACEA electrosensing x16 microtiter plates. Saos-2 cells were seeded at 3x10⁵ cells/ml in 100 µl of serum-free medium without or with fucoxanthinol (625 or 1,250 nM) in the upper chamber with 8-µm pore size and the lower chamber contained serum-free medium supplemented with 50 ng/ml recombinant human stromal cell-derived factor-1α (SDF-1α) (PeproTech Inc.). The ACEA plate was connected to the ACEA Device Station at 37°C and migrated cells were monitored every 1 h in real-time by the ACEA Sensor Analyzer for 6 h and quantitated using ACEA RT-CES Integrated software.

**Transplant metastasis of LM8 tumor cells in mice.** A mouse osteosarcoma cell line, LM8 cells (5x10⁶ cells/mouse) in 0.1 ml phosphate buffered saline was injected subcutaneously into the back of 5-week-old female C3H mice (Japan SLC, Hamamatsu, Japan) on day 0. Treatment was initiated on the day after cell injection. Fucoxanthin was dissolved in soybean oil and 200 mg/kg of fucoxanthin or vehicle only was given by oral gavage every day for 35 days. The mice were weighed once a week and the size of the primary tumor was measured weekly. Mice were also monitored for evidence of morbidity including anorexia, dehydration, dyspnea, decreased activity and grooming behavior. On day 35, all mice were euthanized and autopsied to confirm metastatic lung disease. Lung sections were prepared and the area of lung metastasis was measured. Primary tumors were dissected out for measurement of weight and staining with hematoxylin and eosin (H&E) and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) using a commercial kit (Roche Applied Science, Mannheim, Germany). This experiment was performed according to the Guidelines for Animal Experimentation of the University of the Ryukyus and was approved by the Animal Care and Use Committee of the University of the Ryukyus (permit numbers: 5150, 5274 and 5338).

**Statistical analysis.** Data were expressed as mean ± SD. Differences between groups were examined for statistical significance using the unpaired Student's t-test. A P<0.05 denoted the presence of a statistically significant difference.

**Results**

**Effect of fucoxanthin and fucoxanthinol on osteosarcoma cell viability.** We first examined the effects of carotenoids on the cell viability of osteosarcoma cell lines. Fucoxanthin and fucoxanthinol used in this study reduced cell viability of all 4 osteosarcoma cell lines in a dose-dependent manner (Fig. 1A and B). In contrast, the effects of other carotenoids, β-carotene and astaxanthin, were less significant, although β-carotene reduced LM8 cell viability at 30 µM concentration (Fig. 1C and D).

**Caspase-dependent induction of apoptosis by fucoxanthinol.** The apoptosis-inducing activity of fucoxanthinol was analyzed by immunostaining with Apo2.7, which specifically detects the 38-kDa mitochondrial membrane antigen, 7A6, expressed on the mitochondrial outer membrane during apoptosis (9). The proportion of 7A6-positive cells among Saos-2 cells incubated for 9 h without fucoxanthinol was 0.3%, but increased to 34.9% when the cells were treated with 20 µM fucoxanthinol (Fig. 2A). We next investigated the role of caspases in fucoxanthinol-induced apoptosis by measuring the cleavage of known caspase substrates by immunoblot analysis. Fucoxanthinol cleaved the caspase-3-specific substrate, PARP, in Saos-2 cells in a time- and dose-dependent manner. In addition, fucoxanthinol processed the initiator caspases-8 and -9 and the executioner caspase-3 in Saos-2 cells in a time- and dose-dependent manner (Fig. 2B). We also investigated whether fucoxanthinol can activate the caspases by examining protease activity using fluorescence substrates specific for caspases-3/7, -8 and -9. As shown in Fig. 3A, after treatment
with fucoxanthinol for 9 h, the activities of caspases-3/7, -8 and -9 were all obviously increased in a dose-dependent manner compared with controls.

To investigate further the involvement of the caspase pathway, Saos-2 cells were treated with a broad spectrum caspase inhibitor, Z-VAD-fmk, together with fucoxanthinol. Saos-2 cell treatment with fucoxanthinol decreased the activities of caspases-3/7, -8 and -9 after adding Z-VAD-fmk (Fig. 3A). As shown in Fig. 3B, reduced cell viability induced by fucoxanthinol was significantly diminished by Z-VAD-fmk. These results indicate that fucoxanthinol-induced apoptosis of Saos-2 cells is mediated through caspase activation.

Fucoxanthinol causes G1 cell cycle arrest. We also examined the distribution of cellular DNA contents by flow cytometric analysis. Cultivation of Saos-2 and LM8 cells with 20 µM fucoxanthinol for 9 h increased the population of the cells in the G1 phase, with marked reduction of the S phase, relative to untreated cells (Fig. 4). These results indicate that, together with induction of apoptosis, fucoxanthinol induces G1 cell cycle arrest in osteosarcoma cells.

Effects of fucoxanthinol on the expression of cell cycle regulatory proteins. G1-S progression is influenced by diverse growth signaling pathways that converge on the control of CDK, including CDK4 or CDK6 in conjunction with D type cyclins and CDK2 in conjunction with cyclin E (12). The best characterized substrates of G1 CDKs are the retinoblastoma protein (pRB) and the pRB-related proteins, p107 and p130 (12). Each of these pRB family members can block the progression from G1 into S and is thought to do so, at least in part, by binding to E2F transcription factors and repressing genes that contribute to S phase entry (12). These pRB family proteins are phosphorylated and released from E2F-4 in the late G1 phase of the cell cycle (12). In pRB (-) Saos-2 cells, p130 but not p107 was phosphorylated and released from E2F-4 in a CDK2-dependent process in late G1 and S phase cells (13).
To clarify the molecular mechanism of fucoxanthinol-induced G1 cell cycle arrest, we investigated its effects on the expression of several intracellular regulators of cell cycle by western blot analysis. As shown in Fig. 5A, fucoxanthinol significantly reduced the expression of CDK4, CDK6 and cyclin E in Saos-2 cells in a time-dependent manner, but had no effect on CDK2, cyclin D1 and cyclin D2 expression levels. Furthermore, fucoxanthinol inhibited phosphorylation of p130. Comparable loading of protein was confirmed with a specific antibody for the housekeeping gene product actin (Fig. 5A). These results indicate that fucoxanthinol dephosphorylates p130 by inhibiting the expression of CDK4, CDK6 and cyclin E, resulting in G1 cell cycle arrest.

Effects of fucoxanthinol on the expression of apoptosis regulatory proteins. To elucidate the possible molecular targets of fucoxanthinol-induced apoptosis of Saos-2 cells, we examined the expression of important apoptosis regulators. As shown in Fig. 5B, fucoxanthinol potently reduced the expression of anti-apoptotic proteins survivin, XIAP, Bcl-2 and Bcl-xL in a time- and dose-dependent manner, but had no effect on pro-apoptotic protein Bak.

Inhibitory effects of fucoxanthinol on Akt activation. Members of the NF-κB family control the expression of several genes that regulate cell survival, proliferation and apoptosis (14). NF-κB is inactive in the cytosol because it is bound to IκBα and becomes active after IκBα has been phosphorylated and subsequently degraded (15). Because CDK4, CDK6, cyclin E, survivin, XIAP, Bcl-2 and Bcl-xL are controlled by NF-κB (16-22), we determined the effects of fucoxanthinol on the phosphorylation and degradation of IκBα. As shown in Fig. 5B, treatment of Saos-2 cells with fucoxanthinol did not affect the level of total IκBα. In addition, phosphorylated IκBα could not be detected in untreated or fucoxanthinol-treated Saos-2 cells (Fig. 5B). The activation of NF-κB in Saos-2 cells in response to TNF-α stimulus...
was assessed by western blotting and EMSA. EMSA detects nuclear factor binding to a specific consensus NF-κB sequence. As shown in Fig. 5C, treatment of Saos-2 cells with TNF-α resulted in increases in IκBα phosphorylation and NF-κB-DNA binding, while basal levels of phosphorylated IκBα as well as NF-κB-DNA binding were not observed in Saos-2 cells. These results show that fucoxanthinol does not affect NF-κB activation.

The phosphatidylinositol 3-kinase (PI3K)-Akt pathway also plays an important role in various cellular processes including cell growth and survival in osteosarcoma cells (23). Akt prevents apoptosis by activating anti-apoptotic signals by phosphorylating GSK3β and caspase-9 and by activating NF-κB (24). To determine whether the Akt activity is associated with the apoptotic effects of fucoxanthinol, we examined the protein expression and phosphorylation level of Akt after fucoxanthinol treatment. Akt was constitutively activated in Saos-2 cells and fucoxanthinol decreased the phosphorylation level of Akt at both Thr308 and Ser473 sites (Fig. 6).

We next examined the effect of fucoxanthinol on the phosphorylation levels of two Akt downstream targets: GSK3β and caspase-9, in Saos-2 cells. As shown in Fig. 6, constitutive phosphorylation of GSK3β and caspase-9 was seen in Saos-2 cells and fucoxanthinol reduced the phosphorylation level. A key downstream target of GSK3β is the proto-oncogene, β-catenin. Fucoxanthinol inhibited GSK3β phosphorylation, thereby maintaining GSK3β in its active form. Active GSK3β induced β-catenin phosphorylation, resulting in increased ubiquitin-mediated proteolysis and decreased levels of signaling-competent β-catenin. Fucoxanthinol reduced the levels of β-catenin in Saos-2 cells (Fig. 6). Akt is phosphorylated at Thr308 in the kinase activation loop mediated by
PDK1. Fucoxanthinol inhibited the phosphorylation of PDK1, but not the total PDK1 (Fig. 6).

**Fucoxanthinol inhibits cell migration and invasion.** Osteosarcoma is characterized by a high metastatic potential. The chemokine SDF-1α and its receptor CXCR4, play a crucial role in adhesion and migration of osteosarcoma cells (25). Fucoxanthinol inhibited SDF-1α-induced migration of Saos-2 cells in a dose-dependent manner (Fig. 7A). The effect of fucoxanthinol on invasion of Saos-2 cells was examined by using a type I collagen-coated transwell cell culture chambers. Saos-2 cells moved from the top chamber to the bottom chamber in the absence of fucoxanthinol, but the penetration of type I collagen-coated filter by Saos-2 cells was inhibited in the presence of fucoxanthinol (Fig. 7B).

We have recently reported that MMP-1, otherwise known as collagenase-1, plays important roles in invasion of osteosarcoma cells (26). MMP-1 was highly expressed in the high-frequent pulmonary metastatic human osteosarcoma cell line 143B compared with MNNG cells (26). Saos-2 cells also expressed MMP-1 mRNA (Fig. 7C) and fucoxanthinol inhibited such expression in a time- and dose-dependent manner (Fig. 7D).

**Fucoxanthinol inhibits AP-1 activation.** We reported previously that AP-1, otherwise known as collagenase-1, plays important roles in invasion of osteosarcoma cells (26). MMP-1 was highly expressed in the high-frequent pulmonary metastatic human osteosarcoma cell line 143B compared with MNNG cells (26). Saos-2 cells also expressed MMP-1 mRNA (Fig. 7C) and fucoxanthinol inhibited such expression in a time- and dose-dependent manner (Fig. 7D).
Figure 9. Inhibition of development of tumors and appearance of pulmonary metastases by fucoxanthin. LM8 cells were inoculated subcutaneously into the back of C3H mice on day 0. The mice were treated orally with 200 mg/kg/day of fucoxanthin or vehicle. (A) Serial changes in primary tumor volume evaluated weekly. The volume of the primary tumor measured at day 28 after inoculation. The horizontal bars represent the mean value for each group. *P<0.05, compared with the control. (B) Tumor weight after removal from fucoxanthin-treated mice and untreated mice at day 35 after inoculation. (D) Serial changes in body weight of mice treated as indicated. Data are mean ± SD in each group. (E) Representative images showing gross appearance of the primary tumor (top panel) and lungs (bottom panel) of mice treated (right) or untreated (left) with fucoxanthin on day 35. (F) Area of lung metastasis in vehicle-treated and fucoxanthin-treated mice. The horizontal bars represent the mean area of each group.

Figure 10. Increased apoptotic cells in the primary tumor and inhibition of pulmonary metastases by fucoxanthin. LM8 cells were inoculated subcutaneously into the back of C3H mice on day 0. The mice were treated with fucoxanthin or vehicle every day. On day 35, the primary tumor and lungs were removed. (A) Representative microscopic photographs of the lungs (H&E staining) of mice untreated (left panels) and treated with (right panels) fucoxanthin on day 35 showing the presence of metastatic nodules in the lungs of untreated mice. Magnification, x50. H&E staining (B) and TUNEL assay (C) of sections of the primary tumor of mice untreated (left panels) and treated (right panels) with fucoxanthin on day 35. Magnification, x400.
NF-κB site from the IL-2Rα promoter could not compete with the labeled AP-1 probe (Fig. 8A, lanes 3 and 5). The exact composition of the transcription factor DNA-protein complex in Saos-2 cells was analyzed by supershift assay using specific antibodies. These experiments identified Fra-2, c-Jun and JunD as the predominant components of the AP-1 complex on the MMP-1 AP-1 site in Saos-2 cells (Fig. 8A, lanes 10, 11 and 13). Fucoxanthinol decreased the protein complex bound to the AP-1 site in nuclear extracts derived from Saos-2 cells and such effect was time-dependent (Fig. 8B), suggesting that fucoxanthinol suppressed the invasion of Saos-2 cells by suppressing the AP-1 signaling pathway. The inhibitory effect also appeared specific to AP-1 and not related to cell death, because no significant change in binding of Oct-1 was observed after treatment with fucoxanthinol.

model. Subcutaneous inoculation of LM8 cells was followed by the appearance of tumors that exhibited rapid growth, reaching 726 mm³ in size within 4 weeks (Fig. 9A and B). Three of 13 mice inoculated with LM8 cells died between 4 and 5 weeks after inoculation (Table I). Multiple metastatic nodules were found macroscopically and confirmed histopathologically in the lungs of 8 of 10 LM8-inoculated mice (80%) at 5 weeks after inoculation (Table I, Fig. 9E, bottom panel, left and 10A, left panels). Treatment of these mice with 200 mg/kg/day of fucoxanthin after inoculation of LM8 showed significant reduction of the primary tumor volume associated with increased apoptotic cells in the tumor as judged by H&E staining and TUNEL assay (Fig. 9A, B and E, top panel, right, 10B and C, right panels), although the difference in tumor weight after 5 weeks of treatment, compared with control, was less conspicuous (Fig. 9C). The mean tumor volume was lower in mice treated with fucoxanthin than with control, albeit statistically insignificant after 5 weeks of treatment, because the 3 untreated mice with huge tumors died between 4 and 5 weeks after inoculation (data not shown). Although 4 of 8 fucoxanthin-treated mice (50%) had visible gross lung nodules, all mice were still alive at 5 weeks after inoculation (Table I). The area of lung metastasis in fucoxanthin-treated mice tended to be smaller than the vehicle-treated control mice but the difference was not significant (Fig. 9F). We found little difference in body weight of the fucoxanthin-treated and untreated groups (Fig. 9D) and no obvious abnormalities in the treated mice at this dosage.

Discussion

The main issue addressed by this study is whether carotenoids have any effects on osteosarcoma cells and the possible molecular mechanisms of any such effect. The results showed that fucoxanthin isolated from C. okamuranus Tokida and fucoxanthinol prepared by enzymatic hydrolysis of purified fucoxanthin exhibited anti-osteosarcoma properties; these

<table>
<thead>
<tr>
<th>Mouse no.</th>
<th>Treatment</th>
<th>Lung metastases at 35 days</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>+</td>
<td>Alive</td>
</tr>
<tr>
<td>2</td>
<td>Control</td>
<td>++</td>
<td>Alive</td>
</tr>
<tr>
<td>3</td>
<td>Control</td>
<td>+</td>
<td>Alive</td>
</tr>
<tr>
<td>4</td>
<td>Control</td>
<td>NE</td>
<td>Dead*a</td>
</tr>
<tr>
<td>5</td>
<td>Control</td>
<td>++</td>
<td>Alive</td>
</tr>
<tr>
<td>6</td>
<td>Control</td>
<td>+++</td>
<td>Alive</td>
</tr>
<tr>
<td>7</td>
<td>Control</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>8</td>
<td>Control</td>
<td>++</td>
<td>Alive</td>
</tr>
<tr>
<td>9</td>
<td>Control</td>
<td>NE</td>
<td>Dead*a</td>
</tr>
<tr>
<td>10</td>
<td>Control</td>
<td>NE</td>
<td>Dead*a</td>
</tr>
<tr>
<td>11</td>
<td>Control</td>
<td>++</td>
<td>Alive</td>
</tr>
<tr>
<td>12</td>
<td>Control</td>
<td>++</td>
<td>Alive</td>
</tr>
<tr>
<td>13</td>
<td>Control</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>8/10 (80%)</td>
<td>10/13 (77%)</td>
</tr>
</tbody>
</table>

*Mice died between days 28 and 35 after inoculation. The level of lung metastasis was scored as numerous (+++), moderate (++), small (+), or absent (-). NE, not examined.

Fucoxanthin reduces primary tumor size and pulmonary metastasis in mice. Inoculation of the murine osteosarcoma cell line, LM8, into the skin of C3H mice results in the formation of tumors with high metastatic potential to the lung (27). We assessed the antitumor activity of fucoxanthin using this
properties appear to be at least in part attributable to the inhibition of Akt and AP-1 signal pathways in osteosarcoma cells.

In this study, we demonstrated that fucoxanthin and fucoxanthinol decreased cell viability in the 4 tested osteosarcoma cell lines in a concentration-dependent manner. The inhibitory effects of fucoxanthin and fucoxanthinol on the cell viability were remarkable compared with other carotenoids. Further, we studied the effect of fucoxanthinol on the induction of apoptosis and the results demonstrated that fucoxanthinol induced apoptosis through activation of caspases-3, -8 and -9 in Saos-2 cells. Inhibition of cell viability in Saos-2 cells treated with fucoxanthinol was significantly diminished by the general caspase inhibitor Z-VAD-fmk. However, since Z-VAD-fmk partially diminished a decrease in cell viability, it is suggested that the apoptosis signaling in Saos-2 cells by fucoxanthinol is mediated by both caspase-dependent and -independent pathways. The apoptotic effect of fucoxanthinol was associated with suppression of expression of survivin, XIAP, Bcl-2 and Bcl-xL. Dephosphorylation of p130 through the downregulation of CDK4, CDK6 and cyclin E also seems to contribute to the activation of G1 cell cycle arrest.

The Akt signaling pathway is important for cell survival and apoptosis (24). Increased Akt phosphorylation has been reported in osteosarcoma cell lines U2OS and MG63 (23). The present results showed that Akt is constitutively phosphorylated at both Ser473 and Thr308 in Saos-2 cells. Fucoxanthinol inhibited Akt phosphorylation at these two sites. As the downstream targets of Akt, GSK3β and caspase-9 have been reported to be involved in the regulation of cell survival. Akt promotes cell survival by phosphorylating GSK3β and caspase-9, which inactivates them and prevents apoptosis (24). The results showed constitutive phosphorylation of GSK3β and caspase-9 in Saos-2 cells and fucoxanthinol suppressed the phosphorylation levels. To further confirm the role of GSK3β in fucoxanthin-induced apoptosis, we examined the expression of β-catenin, a downstream target of GSK3β. The results showed that fucoxanthinol reduced the level of β-catenin. NF-κB is activated by stimulation of the IκB kinase complex, which phosphorylates IκBα. IκB kinase phosphorylation by Akt is essential for NF-κB activation (28). However, we could not observe constitutive activation of NF-κB in Saos-2 cells. Basal levels of phosphorylated IκBα and NF-κB RelA as well as NF-κB-DNA binding were not observed in Saos-2 cells (Fig. 5C and data not shown) (29). In addition, fucoxanthinol did not alter the levels of total and phosphorylated IκBα. Thus, fucoxanthinol-induced apoptosis is independent of NF-κB. We investigated the effect of fucoxanthin on the upstream event of Akt, PDK1. The results demonstrated that fucoxanthin inhibited the expression of phosphorylated PDK1, but not the total level of PDK1. Akt promoted cell survival by inhibiting apoptosis through its ability to phosphorylate and inactivate several targets, which are components of the intrinsic cell death machinery, including the Bcl-2 and IAP family members. Akt can be an upstream regulator of XIAP, which possess an Akt phosphorylation site (30). Furthermore, survivin and Bcl-2 have been shown to be downstream targets of Akt signaling (31,32). Thus, inhibition of Akt pathway mediates, at least in part, the induction of apoptosis and cell cycle arrest in G1 phase induced by fucoxanthinol.

The mean 5-year survival rate of patients with metastasizing osteosarcoma is only 20-30% (33). Therefore, many investigators have focused on the development of new agents for blocking cancer cell metastasis. MMPs play an important role in tumor angiogenesis, metastasis and stimulation of growth factor release from the extracellular matrices (34). We investigated the anti-metastatic functions of fucoxanthinol in the migration and invasion of Saos-2 cells and the results indicated that fucoxanthinol can inhibit in vitro migration and invasion ability of Saos-2 cells.

Our results also showed that fucoxanthinol inhibited MMP-1 expression. MMP-1 is involved in the invasive metastatic potential of osteosarcoma cells (26). Recent studies showed that MMP-1 silencing inhibits osteosarcoma pulmonary metastases in vivo (35). Thus, inhibition of MMP-1 expression or enzyme activity can be an early target to prevent cancer metastasis. We have reported that AP-1 signaling pathway plays a crucial role in constitutive transactivation of MMP-1 in osteosarcoma cells (26). Fucoxanthinol inhibited AP-1-DNA binding activity. Taken together, our findings suggest that fucoxanthinol has anti-metastatic activities by blocking AP-1 resulting in inhibition of MMP-1.

The concentration of fucoxanthin or fucoxanthinol used in this study to exhibit anti-osteosarcoma effects may not be pharmacologically achievable in humans. Because the concentrations that induce antitumor effects in vitro often differ from those in vivo, future in vivo efficacy studies with fucoxanthin or fucoxanthinol should be conducted in animal models. In the present study, we described the antitumor properties of fucoxanthin in mice.

The novel findings of this study are that fucoxanthin and fucoxanthinol are potent inducers of apoptosis and cell cycle arrest, with anti-metastatic properties in osteosarcoma cells at least in part via inhibition of Akt and AP-1. A hypothetical model for the actions of fucoxanthin and fucoxanthinol is shown in Fig. 11. Based on these findings, it is tempting to speculate that fucoxanthin or fucoxanthinol alone or in combination with other conventional chemotherapeutics may be potentially useful in the treatment of osteosarcoma.

References


